Dr. Anthony Zeitman -Radiation Therapy for high risk prostate cancer patients

Dr. Anthony Zietman from Massachusetts General Hospital Harvard Medical School discusses radiation therapy for patient in intermediate to high risk prostate cancer.  Lecture given at the PCRI 2014 annual meeting. www.pcri.org

Posted in Treatments for Prostate Cancer | Leave a comment

OligoMetastatic Prostate Cancer – Lecture by Eugene Kwon M.D.

Eugene Kwon M.D.  at the PCRI 2014 Annual Meeting.

Topic : OligoMetastatic Prostate Cancer Disease.

Dr. Kwon brings examples of Choline 11 PET scans as a tool to find location of metastatic lesions.  These  targets can be treated and also watched over a period of time to monitor the status of the activity of the tumor.

 


Click here to send a video question and you will get an e mail video reply

Posted in Choline 11 PET Scan, Diagnosis, Metastatic Disease, PET scans, Treatments for Prostate Cancer | Leave a comment

Circulating Epithelial Tumor Cells

Interview with Peter Pachmann about Mmaintrac



Click here to send a video question and you will get an e mail video reply

Posted in Biomarker, CETC, CTC, Diagnosis, Metastatic Disease, Treatments for Prostate Cancer | Leave a comment

Focal MRI Guided Laser Therapy Study

 

Additional reading  Role of multiparamteric MRI imaging in focal therapy for prostate cancer.

 

Advantages of focal laser therapy:

1) Total ablation process takes up to 3 minutes per laser fiber.

2) Damage predicted with with MR temperature mapping correlated with damage seen on follow up studies.

3)  Patient discharged 3 hours after treatment.

4)  No post treatment Incontinence, or rectal injury.

5)  MRI has an inherent high spatial resolution and temporal resolution.

6)  Ablation zone is sharply demarcated compared with other ablation techniques.

 

 

Posted in Ask Dr. Barken, Focal Therapy, Laser, MRI Guided Focal, Treatments for Prostate Cancer | 2 Comments

Phase III Prostvac Clinical Study

Immune Therapy is an important tool for advanced prostate cancer disease, especially in older patients for whom chemotherapy is excluded because of other serious medical problems.
Dr. Barken presents the Prostvac Clinical Study Phase III with a video clip featuring Dr. James Gulley who discusses the mode of action of Prostvac. The uniqueness of Prostvac is explained by Dr. Barken.
Patients selected for the study are those with Metastatic Castration Resistant Prostate Cancer, but who are minimally or only mildly symptomatic.
In addition, Dr. Barken mentions pending clinical studies for patients with low risk disease. For patients who are candidates for active surveillance, the immune therapy with Prostvac will be a primary treatment. The clinical approach of combining Prostvac with Anti Androgens (Enzalutamide/Xtandi) is emphasized.
Dr. Israel Barken is the Medical Director of the Prostate Cancer Research and Education Foundation. www.pcref.org

 

Mechanism of action of Prostvac explained by Dr. James Gulley.

==============================================================

More info: http://www.ustoo.org/PDFs/PROSTVAC%20factsheet%20FINAL.pdf

For more about Immunology studies, visit AskDrBarken.wordpress.com
=====================================================================

Click here to send a video question and you will get an e mail video reply

Posted in Active Surveillance, Ask Dr. Barken, Castration Resistant Prostate Cancer, Clinical Trials, Immune Therapy, Metastatic Disease, Prostate Cancer, PSA | Leave a comment

Long Term Results of Optimized Focal Cryotherapy

Long Term Results of Optimized Focal Cryotherapy

These days, there is a lot of interest in using focal therapy for prostate cancer. There are a number of modalities to achieve the destruction of the tumor locally within the prostate. Obviously with better identifying and targeting the location of the tumor within the prostate gland, there is less likelihood to injure important tissue outside the prostate. Therefore ,there is a great benefit in avoiding complication like impotence or incontinence and improve quality of life.
But there are still important questions to ask:

How well is the destruction of the tumor achieved?

What is the long term data to demonstrate eradication of the tumor?
In Dr. Gary Onik article, described in the video below, there is information about follow up of 10 years with good results of achieving destruction of the tumor. Side effects were also very minimal.
This put the Focal Cryoablation of the prostate in an appealing position of choice to patients who are candidates for Active Surveillance or Radical Treatments.  The focal cryotherapy provides the quality of life of active surveillance with the same outcome that radical treatments provide.

The focal Cryoablation of the prostate is the only treatment modality that has this length of follow up with excellent results of disease free survivals and overall survivals.


Click here to send a video question and you will get an e mail video reply

 

Posted in Active Surveillance, Focal Therapy, Prostate Cancer, Treatments for Prostate Cancer | Tagged , , , | Leave a comment

New Prostate Cancer Immunotherapy- Prostvac

NIH meeting

Dr. Barken introduces the New Prostate Cancer Immune Therapy for earlier stages of Prostate Cancer.  Please watch the video below and see what  he learned at the National Cancer Institute recent conference mentioned above.

Dr. James Gulley explains the Prostvac approach.

Prostvac and Enzalutamide for patients who have biochemical recurrence after surgery or radiation.   copy and paste the url – http://clinicaltrials.gov/ct2/show/NCT01875250?term=Prostvac+Phase+III&rank=4

Posted in Clinical Trials, Immune Therapy, Prostate Cancer, PSA, Treatments for Prostate Cancer | Tagged | Leave a comment

Enzalutamide and Prostvac for patients with PSA only disease after primary treatment

This very significant development could become the standard treatment for prostate cancer in the future.

 

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov  Identifier: NCT01875250

Posted in Immune Therapy, Prostate Cancer, PSA, Radiation Therapy, Radical Prostatectomy | Leave a comment

Enzalutamide in High Risk Prostate Cancer


Patients after radical prostatectomy with High Risk pathological features are recruited to a new study at the Cleveland clinic.

 

 

Posted in Treatments for Prostate Cancer | Leave a comment

Combidex- Dr. Jelle Barentsz discusses the latest about this imaging test

Dr. Jelle Barentsz discusses the latest information about the utility of Combidex (2014)
Dr. Israel Barken Recently asked Dr. Barentsz to compare Combidex to other imaging techniques , especially looking at recurrent prostate cancer after primary treatment.

For further questions, please write to j.barentsz@rad.umcn.nl   or  call-

T +31 24 8186646, internal number 86646, secretary +31 024 3619196

CV: http://runmc-radiology.nl/index.php/Person?name=Jelle_Barentsz Barentsz picture

Posted in Treatments for Prostate Cancer | Leave a comment